The short answer
Cannabinoid-containing cannabis products may worsen sleepiness or impairment during ropinirole treatment. Review the exact product with your prescriber, including its THC and CBD amounts and whether it is swallowed or smoked. The evidence does not support treating every Cannabis sativa product as equivalent.
What this answer covers
Characterized oral THC/CBD cannabis extracts. Hempseed foods, cannabinoid-free preparations, isolated CBD and smoke exposure are distinct.
- Supplement or preparation
- Cannabis sativa
- Medication ingredient
- ropinirole
What oral cannabis studies show
A healthy-adult trial found more sedation and impairment from a high-CBD, THC-containing oral extract than from the THC-only extract or placebo conditions. The result depends on those specific products and doses; it does not establish the effect of every hemp product.
What is known in Parkinson disease
A short placebo-controlled trial of oral CBD/THC extract did not show a significant motor benefit. Some sleep and cognition outcomes favored placebo, and mild adverse events were more frequent with the extract. The accessible report does not separate outcomes for ropinirole users.
Smoking and cannabinoids are different questions
The ropinirole label reports lower exposure in cigarette smokers. That does not describe the effect of swallowing THC or CBD. Tell your prescriber about smoking changes as well as cannabinoid products, because the route and ingredients change the assessment.
If sleepiness develops
Contact your prescriber promptly for new marked daytime sleepiness or falling asleep during ordinary activities. Do not drive or use machinery if this occurs. Ropinirole can cause sleep episodes even without a warning feeling of drowsiness; the treating team should decide how to change treatment.
Evidence and practical considerations
Side effects & toxicity
Characterized oral cannabinoid extracts have impairment signals relevant to ropinirole-related sleepiness, but the exact combination risk is not quantified.
- Exact scope
- Characterized oral THC/CBD cannabis extracts. Hempseed foods, cannabinoid-free preparations, isolated CBD and smoke exposure are distinct. with Oral immediate-release ropinirole; hydrochloride salt expressed as equivalent free base in the inspected label.
- Medication form and route
- oral ropinirole; supplement preparation and route described in scope
- Timing or duration
- No exact-pair safe duration or protective spacing interval established.
What remains uncertain
- Oral trials do not measure a ropinirole-specific interaction. Cigarette smoking effects in the label are not evidence of the same effect from every cannabis product.
Factors that may matter: THC and CBD content; oral versus smoked exposure; other sedating medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral immediate-release ropinirole tablets for Parkinson disease or primary restless legs syndrome.
Ropinirole can cause somnolence, sudden sleep episodes and orthostatic hypotension. Concomitant sedating medicines or alcohol can increase sleepiness risk. CYP1A2 is its major metabolic enzyme; inhibitors and inducers may alter clearance. Ciprofloxacin increased exposure, whereas theophylline did not. Cigarette smokers had lower dose-normalized exposure than nonsmokers in a small RLS comparison.
How this applies: Exact oral ropinirole risk and metabolic context; section 11 justifies hydrochloride-to-free-base active-moiety identity only.
None of these ten supplement pairs is directly tested in this label. Cigarette smoking is not interchangeable with oral cannabis or isolated CBD; ciprofloxacin results are not caffeine results. No extended-release kinetic equivalence assumed.
Source 2: randomized double-blind crossover clinical trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 18 healthy adults not using cannabis for at least 30 days.
CBD-rich/THC-containing extract produced more self-reported sedation and greater cognitive and psychomotor impairment than THC-only extract and placebo conditions.
How this applies: Preparation-specific impairment concern; not proof that every Cannabis sativa product increases ropinirole toxicity.
No ropinirole; very high CBD exposure, oral route, infrequent users and concomitant probe cocktail. No inference to hempseed foods or non-cannabinoid preparations.
Source 3: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 61 participants with Parkinson disease: 31 active and 30 placebo.
No significant between-group benefit on motor score. Some sleep, cognition and daily-living assessments favored placebo; adverse events were mostly mild and more frequent with active extract.
How this applies: Relevant disease-population context; does not establish a specific ropinirole interaction.
Short duration and strong placebo response. Original abstract does not provide a ropinirole-specific subgroup; full text unavailable.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources inspected and exact current claim adjudicated; no clinical review asserted. | |
| Research summary published |
Article revision: d2e69968669ab2bf
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.